Trial reportDigestive diseases and sciences2004
On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction.
Trial report in Digestive diseases and sciences, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Deprescribing versus continuation of chronic proton pump inhibitor use in adults.The Cochrane database of systematic reviews · 2017Pooled it
- Patient satisfaction with medication for gastroesophageal reflux disease: a systematic review.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2012Pooled it
- Sustained efficacy following resolution of frequent heartburn with an over-the-counter regimen of esomeprazole 20 mg or placebo for 14 days: two randomized trials.BMC gastroenterology · 2018Trial
- A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease.World journal of gastroenterology · 2012Trial
- Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2007Trial
- Approaches to Deprescribing Proton Pump Inhibitors in Clinical Practice: A Systematic Review.Journal of clinical medicine · 2024Review
- Cost-effective Analysis of Proton Pump Inhibitors in Long-term Management of Gastroesophageal Reflux Disease: A Narrative Review.Hospital pharmacy · 2020Review
- The effect of gastroesophageal flap valve appearance on the management of patients with symptoms of gastroesophageal reflux disease.Digestive diseases and sciences · 2009Article
- Accounting for the effect of GERD symptoms on patients' health-related quality of life: supporting optimal disease management by primary care physicians.International journal of clinical practice · 2007Review
- A review of rabeprazole in the treatment of acid-related diseases.Therapeutics and clinical risk management · 2007Article
- Effects of pantoprazole 20 mg in mildgastroesophageal reflux disease: Once-daily treatment in the acute phase, and comparison of on-demand versus continuous treatment in the long term.Current therapeutic research, clinical and experimental · 2005Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
On-demand therapy is effective for maintaining symptoms control in nonerosive gastroesophageal reflux disease (GERD). Our aim was to assess the clinical effectiveness of on-demand therapy with a proton pump inhibitor (PPI) in mild GERD (nonerosive and low-grade esophagitis), its impact on health-related quality of life (HRQoL), and the degree of patient satisfaction. Fifty-five patients (17 with nonerosive GERD and 38 with low-grade esophagitis) were treated with rabeprazole, 20 mg/day. The healed patients started on-demand therapy. We evaluated symptoms (clinical questionnaire), HRQoL (SF-36 questionnaire), and patient satisfaction (visual analogue scale). Of the 55 patients included, 51 started on-demand therapy for 6 months. Symptom control (heartburn <twice a week) was achieved in over 85% of the patients. The mean (SD) amount of PPI used was 0.3 (0.19) tablet/day. The patient satisfaction score at the end of the acute phase was 98 (range, 0-100) and remained high (90; range, 10-100) and stable during on-demand therapy. Short-term treatment normalized the HRQoL scores, which were subsequently maintained during on-demand therapy. On-demand therapy is useful for the clinical management of patients with mild GERD, allowing adequate symptoms control, limiting PPI consumption, and affording important patient satisfaction with normalization of HRQoL.
Indexed as
Identifiers
15309880What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.